Sarah Tasian Laboratory
Researchers at the Center for Childhood Cancer Research (CCCR) are studying perturbations in leukemia cell signal transduction networks for therapeutic intervention in high risk subtypes of childhood leukemias.
Researchers at the Center for Childhood Cancer Research are currently evaluating the use of antibody drug conjugates and targeted small molecule drugs as treatments for acute myeloid leukemia (AML) in a Phase III clinical trial.
Researchers are testing the efficacy of the JAK1/JAK2 inhibitor ruxolitinib with chemotherapy in a phase 2 clinical trial as a treatment for children with newly-diagnosed ALL.
Researchers are analyzing clinical samples and medical outcomes data from AML clinical trials to establish possible molecular links between specific AML germline or somatic mutations and disease progression and treatment responsiveness.
Identifying the underlying genetic causes of high-risk acute lymphocytic leukemia can provide clues to potential therapeutic targets.
Researchers at the CCCR performed chart review for 12 different AEs for pediatric patients enrolled in U.S.-based COG Phase III clinical trials for pediatric acute myeloid leukemia (AML). Results from this analysis showed the current system of AE reporting on cooperative group oncology trials had modest sensitivity and a demonstrable false positive rate.
Researchers at the Center for Childhood Cancer Research are investigating new immunotherapies using chimeric antigen receptor (CAR)-modified T cells to treat children with relapsed and refractory AML.